8-K
filed February 14, 2025, 6:59 PM ET
CIK 0001492674
other material
confidence high
sentiment negative
materiality 1.00
T2 Biosystems, Inc.: restructuring charge — T2 Biosystems cuts substantially all staff after Nasdaq delisting; top execs as consultants
T2 Biosystems, Inc.
- Board approved RIF of substantially all employees; expects $1.0M severance costs in Q1 2025.
- CEO Sperzel, CFO Sprague, GC Gibbs terminated without cause, re-hired as consultants at $276.44-$187.50/hr for 20 hrs/week.
- Nasdaq notified company Feb 10 it will file Form 25 to delist; trading moved to OTC on Feb 12.
- Canceled March 3 special meeting for reverse stock split after delisting determination.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Sperzel was appointed as Chief Executive Officer at T2 Biosystems, Inc..
- Action
- re-appointed
- Role
- Chief Executive Officer
Exact text from the filing
Following the end of their employment, Messrs. Sperzel, Sprague and Gibbs were re-appointed by the Board to serve as the Company’s Chief Executive Officer, Chief Financial Officer and General Counsel, respectively.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Gibbs was appointed as General Counsel at T2 Biosystems, Inc..
- Action
- re-appointed
- Role
- General Counsel
Exact text from the filing
Following the end of their employment, Messrs. Sperzel, Sprague and Gibbs were re-appointed by the Board to serve as the Company’s Chief Executive Officer, Chief Financial Officer and General Counsel, respectively.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Sperzel departed as President and Chief Executive Officer at T2 Biosystems, Inc..
- Action
- terminated without cause
- Role
- President and Chief Executive Officer
Exact text from the filing
John Sperzel, President and Chief Executive Officer, John Sprague, Chief Financial Officer, and Michael Gibbs, Senior Vice President and General Counsel, were terminated without cause from their respective positions, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Michael Gibbs departed as Senior Vice President and General Counsel at T2 Biosystems, Inc..
- Action
- terminated without cause
- Role
- Senior Vice President and General Counsel
Exact text from the filing
John Sperzel, President and Chief Executive Officer, John Sprague, Chief Financial Officer, and Michael Gibbs, Senior Vice President and General Counsel, were terminated without cause from their respective positions, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Sprague departed as Chief Financial Officer at T2 Biosystems, Inc..
- Action
- terminated without cause
- Role
- Chief Financial Officer
Exact text from the filing
John Sperzel, President and Chief Executive Officer, John Sprague, Chief Financial Officer, and Michael Gibbs, Senior Vice President and General Counsel, were terminated without cause from their respective positions, effective immediately.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
John Sprague was appointed as Chief Financial Officer at T2 Biosystems, Inc..
- Action
- re-appointed
- Role
- Chief Financial Officer
Exact text from the filing
Following the end of their employment, Messrs. Sperzel, Sprague and Gibbs were re-appointed by the Board to serve as the Company’s Chief Executive Officer, Chief Financial Officer and General Counsel, respectively.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
T2 Biosystems, Inc. announced a restructuring with charges of approximately $1.0 million (substantially all of its employees).
- Type
- restructuring
- Charge
- approximately $1.0 million
- Headcount
- substantially all of its employees
Exact text from the filing
On February 13, 2025, the Board of Directors (the “Board”) of T2 Biosystems, Inc. (the “Company”) approved a reduction-in-force (the “Reduction-in-Force”) of substantially all of its employees, effective immediately (the “Effective Time”). The Company expects to incur one-time charges and cash expenditures associated with the Reduction-in-Force of approximately $1.0 million, primarily related to employee wages and severance payments, benefits, earned vacation time and related termination costs.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.